dm+d
108539003
Articles
Safety in Lactation: Sympathomimetics for acute cardiac conditions
4 November 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Dobutamine, dopamine and dopexamine are inotropes…
Medicines that are considered safe for use in the acute porphyrias
29 May 2020The UK Porphyria Medicines Information Service (UKPMIS) and Cardiff Porphyria Service produce a list of medicines that are considered to be safe for use in…
Lactation Safety Information
-
No published evidence of safety
Monitor infant’s blood pressure
4 August 2020
New Medicines
BramoxSevere orthostatic hypotension due to autonomic dysfunction - new 10mg tablet formulation
Information
Bramox
New formulation
Brancaster Pharma
Not Known
Development and Regulatory status
Launched
Approved (Licensed)
None
July 2021
Jul 21Bramox is licensed in the UK for use in adults for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate [3].
Jul 21Available in UK. Price = 1x100 10mg Tablets = £120.50 [3,4,5].
Jan 21New formulation approved in the UK. Also approved in the EU [2].
Category
Pro-drug of the pharmacologically active constituent desglymidodrine. Desglymidodrine is a sympathomimetic agent with a direct and selective effect on the peripheral α1-adrenergic receptors. Taken three times daily, up to 30mg/day.
Prevalence is age-dependent, ranging from 5% in patients under 50 years of age to 30% in those over 70 years of age. Orthostatic hypotension frequently contributes to falls and syncopal episodes. In Parkinsons disease the prevalence may be as high as 60%. The majority of patients with orthostatic hypotension are asymptomatic or have a few nonspecific symptoms [1].
Severe orthostatic hypotension due to autonomic dysfunction - new 10mg tablet formulation
Oral